Thus, it appears plausible that glucagon acting via the release of AVP/copeptin from targets in the hypothalamus and posterior pituitary is involved in this regulation and copeptin response is attenuated in obesity. This evidence concerns the gene AVP and obesity due to melanocortin 4 receptor deficiency.